Enzalutamide monotherapy can improve the quality of live for advanced prostate cancer patients. Thank you, Prof. Tombal, for promoting this arm in the Embark trial!
Enzalutamide does not lower testosterone and estrogen, it even increases the level of these. This avoids the following side effects of Lupron significantly:
- hot flushes
- muscle loss
- weight gain
- reduced libido, patients can stay sexually active
- bone loss, no bisphosphonates or Xgeva and Prolia needed
- brain fog
- shrinked testes
On the other hand Enzalutamide monotherapy will cause gynecomastia and breast enlargement. You can take tamoxifen 10-20 mg to avoid that. Radiation of the breast will also help when done before starting with Enzalutamide monotherapy. Another side effect is fatigue. The Embark study will report on further side effects of this therapy.
In these studies side effects of Enzalutamide monotherapy are reported:
It is likely that Apalutamide and Darolutamide can be used as monotherapy as well, but there is no phase III trial to prove it. Enzalutamide monotherapy could probably be used instead of Lupron after radiation too.
Written by
GP24
To view profiles and participate in discussions please or .
That’s interesting as I am due to make a decision about coming off Hormone therapy if my PSA stays undetectable until July and scans at that time are clear.
My MO says he will support my decision ( on Apalutamide as well as ADT) but would rather I stayed on for another 12 months or tried patches. He hasn’t mentioned dropping ADT and staying on Apalutamide as a mono therapy
I understand! Been on Xtandi, Avodart, Finesteride since 2014. Had a really good run. But it’s failing and I’m looking to the next step. That being said, the fatigue was/is killer. Tho, I’ve just adapted and can manage myself fairly well with rest and naps.
As far as my “huge tracks of land”, please see me in this coming May’s Playboy. I’m the centerfold. 🤣😂
my wife tells me a sports bra comes in handy. I can remember the day when a nice set of cones was eye candy but now they just remind me of my “Limpy” No more rising to the occasion!!
This study was done with men who were low risk/intermediate risk PCa who were not previously treated. There was no control arm. Most of the men in this group have advanced stage cancer.
This phase III study was done with patients recurring after RP or RT. It also included high risk patients: "... in men with high-risk nmCSPC and rising PSA concentrations after radical prostatectomy (RP), RT or both". It had three arms, the ADT+Placebo arm was the control arm.
Because the Embark trial has not reported side effects of Xtandi monotherapy, I had added links to two different studies which reported side effects of Xtandi monotherapy. I wrote: "In these studies side effects of Enzalutamide monotherapy are reported:"
We high volume patients should be more careful than GP24 type of patient. I will rather stick to my ADT and if I wish big breasts I would just add bicalutamide. I am in Australia and we have a very strict PBS rules to follow. That is my nightmare.
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.